alan venook, md explains the outcome of phase 3 calgb/swog 80405 study
Published 8 years ago • 76 plays • Length 1:38
Download video MP4
Download video MP3
Similar videos
-
1:41
alan p. venook, md, explains how the 80405 study and its impact on treatment guidelines
-
0:55
dr. venook discusses implications of the calgb/swog 80405 study
-
1:19
alan venook, md on whether calgb/swog 80405 study provides guidance on therapeutic regimen
-
1:05
jeffrey a. meyerhardt, md explains results from the phase 3 calgb/swog 80405 study
-
7:46
a closer look at fire-3 and calgb/swog 80405
-
0:53
jeffrey a. meyerhardt, md discusses the phase 3 calgb/swog 80405 study
-
1:07
dr. venook discusses the results of the 80405 trial
-
1:01
alan venook, md, balancing economics with the efficacy outcomes seen in 80405
-
40:52
part of the whole: the role of the microbiome in extra-intestinal disease - can summit 2022
-
6:49
diseases of the colon & rectum journal
-
6:59
carol allen story
-
1:54
alan venook, md, explains how tumor sidedness affects therapeutic choice
-
2:03
alan venook, md, explains the biological difference between left-sided and right-sided crc tumors
-
8:41
calgb 80405 trial results in metastatic colorectal cancer
-
1:44
alan venook, md, considers how immunotherapy is being integrated into crc treatment algorithms
-
1:01
alan venook, md talks about treatment strategies based on site of primary tumor in crc patients
-
0:48
dr. venook discusses the future of colorectal cancer treatment
-
0:25
alan venook, md on integrating regorafenib and trifluridine into the 2nd line treatment of mcrc
-
2:59
alan venook, md, provides opinions of the opra data in rectal cancer patients presented at asco20
-
2:12
alan venook, md, considers how i-o is evolving towards the first line treatment of colorectal cancer
-
1:30
alan venook, md, discusses vemurafenib and the nccn guidelines for mcrc patients
-
1:05
alan p. venook, md, on integrating immunotherapy into treatment regimens for gastric cancer patients
Clip.africa.com - Privacy-policy